Successful Treatment of Pediatric Generalized Pustular Psoriasis (GPP) with Spesolimab: 5 Case Reports and Evaluations of Circulating IL-36 Levels
Yunliu Chen,Zhaoyang Wang,Yuan Liang,Chunping Shen,Lei Jiao,Xin Xiang,Chaoyang Miao,Zigang Xu
DOI: https://doi.org/10.2147/jir.s485077
IF: 4.5
2024-11-05
Journal of Inflammation Research
Abstract:Yunliu Chen, 1, 2, &ast Zhaoyang Wang, 1, 2, &ast Yuan Liang, 1, 2 Chunping Shen, 1, 2 Lei Jiao, 1, 2 Xin Xiang, 1, 2 Chaoyang Miao, 1, 2 Zigang Xu 1, 2 1 Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijng, People's Republic of China; 2 Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zigang Xu, Email Background: Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening inflammatory cutaneous disease. IL-36 is a key treatment target in GPP. Spesolimab, a humanized monoclonal antibody of the IL-36 receptor, has demonstrated a good efficacy and a favorable safety profile in adults with GPP. However, data on its use in children are scarce. Methods: We treated patients aged 4– 12 years with GPP with a single dose of spesolimab. The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score, GPPGA pustulation sub-score, Generalized Pustular Psoriasis Area and Severity Index (GPPASI), and the Japanese Dermatological Association severity index for GPP were evaluated. The levels of IL-36α, IL-36β, and IL-36γ were detected by the magnetic bead-based immunoassays, and the levels of IL-17A, IL-17C, IFN-γ, TNF, IL-6, and IL-8 were measured by the Olink proximity extension assay technology. Results: We included five patients (four boys and one girl) with a median age was 6.9 years old (range: 4.8 to 10.6 years), and a median age of onset of 1.7 years (range: 3 months– 10 years and 5 months). After 1 week of spesolimab administration, all patients had a total GPPGA score of 0/1 and pustulation subscore of 0, all patients had a GPPASI of 50, and four patients had a GPPASI of 75. Meanwhile, plasma levels of IL-36α, IL-36β, IL-36γ, IL-17A, IL-17C, IFN-γ, TNF, IL-6, IL-8 all decreased, and those of IL-36α, IL-36β, IL-17A, IL-17C, and IL-6 were statistically significant. There was no recurrence after 2 to 8 months of treatment. No other adverse event was recorded apart from one patient who experienced an upper respiratory infection in the first week. Conclusion: Spesolimab might be a prospective option for children aged 4 to 12 years. Keywords: generalized pustular psoriasis, pediatrics, spesolimab, IL-36R Generalized pustular psoriasis (GPP) is a rare chronic, relapsing, and severe inflammatory cutaneous disease characterized by generalized pustular edematous erythema, and usually associated with fever, headaches, asthenia, myalgia, and raised C-reactive protein (CRP) level and white blood cell count (WBC). 1 Most GPP patients who present with an earlier onset of disease and no history of psoriasis vulgaris have a homozygous or compound heterozygous mutation of the IL36RN gene. 2,3 Moreover, patients with alternative genetic mutation of IL-36 associated inflammatory cascade, such as CARD14, AP1S3 , and MPO , could have similar phenotypes. 4 The IL-36 pathway plays a central role in the pathogenesis of GPP. 5 IL-36 is a pro-inflammatory cytokine, with subunits IL-36α, IL-36β, and IL-36γ, belonging to the IL-1 cytokines family. Upon binding to its receptor, IL-36 activates nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signal pathways resulting in the secretion of extensive pro-inflammatory cytokines and chemokines, such as IL-36 precursors, IL-1β, TNF-α, IL-6, IL-23, CXCL8, CXCL1, and CXCL2. 6 Those chemokines and cytokines recruit and activate immune cells, hence forming an inflammatory loop. 6 Dysfunction in the IL-36 receptor (IL-36R) results in an overactivity of the inflammatory cascade. GPP always requires systemic drugs, as topical drugs alone are insufficient. 7 Biologic agents targeting TNF-α, IL-23, IL-17, and IL-36, or their receptors might be good candidates. 8 Considering the key role of IL-36 in GPP, 5 inhibitors of IL-36 or IL-36R could be effective. Spesolimab is a humanized monoclonal antibody of the IL-36R, which could inhibit the over-activation of the IL-36/IL-36R signal. Moreover, spesolimab has been approved by the US Food and Drug Administration, European Medicines Agency, and China Food and Drug Administration to treat GPP in adults. In china, all treatments for GPP are off-label except spesolimab, which was approved in 2022. However, data on its use in children under 12 years with GPP is scarce. We present five chi -Abstract Truncated-
immunology